Ascendis Pharma A (ASND) Payables (2012 - 2026)

Ascendis Pharma A (ASND) has 15 years of Payables data on file, last reported at $616.7 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 9.81% year-over-year to $616.7 million; the trailing twelve-month figure through Mar 2026 stood at $616.7 million (up 9.81% YoY), and the FY2025 full-year result was $605.4 million, up 0.85% from the prior year.
• Payables climbed to $616.7 million in Q1 2026, from $605.4 million in the prior quarter.
• In the past five years, Payables ranged from a high of $730.5 million in Q3 2023 to a low of $498.5 million in Q4 2022.
• A 5-year average of $596.8 million and a median of $592.6 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables soared 1048.72% in 2022 and slipped 25.23% in 2024, its largest moves.
• Tracing ASND's Payables over 5 years: stood at $498.5 million in 2022, then gained by 8.28% to $539.8 million in 2023, then climbed by 9.8% to $592.6 million in 2024, then climbed by 2.15% to $605.4 million in 2025, then climbed by 1.87% to $616.7 million in 2026.
• Business Quant data shows ASND's Payables at $616.7 million in Q1 2026, $605.4 million in Q4 2025, and $590.2 million in Q3 2025.